Amphastar Pharmaceuticals Inc’s recently made public that its Director Petersen Floyd F. unloaded Company’s shares for reported $12835.0 on Jun 02 ’25. In the deal valued at $25.67 per share,500 shares were sold. As a result of this transaction, Petersen Floyd F. now holds 72,909 shares worth roughly $1.96 million.
Then, Petersen Floyd F. bought 500 shares, generating $12,805 in total proceeds.
Before that, Petersen Floyd F. sold 500 shares. Amphastar Pharmaceuticals Inc shares valued at $12,041 were divested by the Director at a price of $24.08 per share. As a result of the transaction, Petersen Floyd F. now holds 73,409 shares, worth roughly $1.98 million.
JP Morgan downgraded its Amphastar Pharmaceuticals Inc [AMPH] rating to a Neutral from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who decreased its forecast for the stock in early February from “an Overweight” to “a Neutral”. Wells Fargo began covering AMPH with “an Equal weight” recommendation on November 22, 2024. JP Morgan started covering the stock on March 05, 2024. It rated AMPH as “an Overweight”.
Price Performance Review of AMPH
On Tuesday, Amphastar Pharmaceuticals Inc [NASDAQ:AMPH] saw its stock jump 1.13% to $26.92. Over the last five days, the stock has gained 3.50%. Amphastar Pharmaceuticals Inc shares have fallen nearly -27.50% since the year began. Nevertheless, the stocks have fallen -34.26% over the past one year.
How much short interest is there in Amphastar Pharmaceuticals Inc?
A steep rise in short interest was recorded in Amphastar Pharmaceuticals Inc stocks on 2025-05-15, growing by 1.04 million shares to a total of 4.01 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 2.97 million shares. There was a rise of 25.92%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 17, 2023 when BofA Securities began covering the stock and recommended ‘”a Neutral”‘ rating along with a $63 price target.
